Cambridge Biomedical's  2018 Spring Luncheon

Title: Development of the Next Generation of Oncology Therapeutics: Allogeneic, Off-the-Shelf CAR T-Cell Therapies

Speaker: Andrew Garton, PhD, Associate Director, Translational Sciences, Cellectis Inc.

Abstract: Cellectis has developed a platform for generating chimeric antigen receptor (CAR)-redirected T-cells from third-party healthy donors using transcription activator-like effector nucleases (TALEN®). Nuclease mediated inactivation of the TCR alpha abrogates the potential for T-cells bearing alloreactive TCR's to mediate Graft versus Host Disease (GvHD), a potential concern with using unmatched donor-derived CAR T-cells. Additional gene inactivation events can be incorporated, permitting resistance to lymphodepleting or chemotherapeutic agents, resistance to tumor inhibition or suppression of cross T-cell reactions. Two products, targeting CD19 and CD123, have already begun early stage clinical testing in multiple indications. Such allogeneic “off-the-shelf” CAR T-cell products will permit a wider application of CAR technology and potentially lead to a new paradigm in cancer treatment.

Andrew Garton, Ph.D.

Dr. Garton is the Associate Director of Translational Sciences at Cellectis. As a drug discovery biologist and pharmacologist with 18 years’ experience in industry he primarily supported oncology drug discovery and development programs. Over that time he contributed to the discovery and development of 9 clinical candidates, including small molecule and monoclonal antibody therapeutic agents. Prior to Cellectis he contributed as a Director at Astellas Pharma leading in vivo pharmacology and ADME studies.  He earned his PH.D at Newcastle University and completed his Post-doctoral program at Cold Spring Harbor.


Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells. To find out more about them, visit their website:

To lean more, please contact